BioSpace News Archive

Completed upsized initial public offering of $90.8 million in gross proceeds

TherapeuticsMD, Inc. announced that the company will participate in the Stifel 2019 Healthcare Conference in New York City. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conference.

Phase 1/2 trial ongoing with multiple patients dosed in GB1275 monotherapy dose escalation

Pear Therapeutics, Inc., the leader in prescription digital therapeutics, announced that Christopher D.T. Guiffre, J.D., M.B.A., Chief Financial Officer and Chief Operating Officer, will participate in two upcoming investor conferences.

Acorda Therapeutics, Inc. announced that Jane Wasman, President, International & General Counsel, is resigning from the company effective at the end of this year.

Topline data for Phase 3 Clinical Trial of DEXTENZA for Ocular Itching Associated with Allergic Conjunctivitis Anticipated in First Half of 2020

Bristol-Myers Squibb Company announced the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the indentures governing the Celgene Notes.

Company Plans to Use Previously Announced Positive Zimura Clinical Trial as One of Two Pivotal Trials

Breakthrough quarter with CMS NTAP reimbursement and endorsement; new multi-million dollar government contract; Contract with Premier; and $1.4 million in product revenue

Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, announced that company management will make a corporate presentation and host 1x1 meetings at the 10th Annual Jefferies 2019 London Healthcare Conference, being held in London on November 20 & 21.